Seronegative myasthenia gravis. Subtypes and clinical manifestations

Approximately 10-15% of patients diagnosed with Myasthenia gravis do not have detectable antibodies in standard tests. This may be due to the presence of pathogenic antibodies against postsynaptic membrane antigens other than AChR, or the antibody levels may be below the detection limit. The discovery of low-affinity anti-AChR, anti-MuSk, ani-LRP4, anti-agrin, anti-cortactin antibodies represents a considerable advance in the understanding of the pathophysiology. In recent years, significant progress has been made in the development of antigen-specific therapies that specifically target immune cells or autoantibodies involved in the autoimmune response.